Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $78,788 | 17 | 80.6% |
| Travel and Lodging | $14,999 | 15 | 15.3% |
| Unspecified | $2,990 | 3 | 3.1% |
| Food and Beverage | $1,031 | 6 | 1.1% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $69,008 | 21 | $0 (2024) |
| PFIZER LIMITED | $10,406 | 4 | $0 (2023) |
| Mallinckrodt Hospital Products Inc. | $5,799 | 2 | $0 (2022) |
| AstraZeneca UK Limited | $5,500 | 4 | $0 (2024) |
| Novo Nordisk AS | $2,325 | 1 | $0 (2023) |
| Deciphera Pharmaceuticals Inc. | $2,170 | 2 | $0 (2022) |
| Bausch Health US, LLC | $1,750 | 2 | $0 (2019) |
| Spark Therapeutics, Inc. | $848.85 | 5 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $13,495 | 6 | Novo Nordisk Inc ($11,845) |
| 2023 | $30,378 | 12 | Novo Nordisk Inc ($14,347) |
| 2022 | $34,093 | 12 | Novo Nordisk Inc ($26,504) |
| 2021 | $17,243 | 4 | Novo Nordisk Inc ($16,313) |
| 2019 | $2,260 | 6 | Bausch Health US, LLC ($1,750) |
| 2018 | $338.58 | 1 | Spark Therapeutics, Inc. ($338.58) |
All Payment Transactions
41 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/19/2024 | Novo Nordisk Inc | — | Consulting Fee | Cash or cash equivalent | $10,656.25 | General |
| 11/19/2024 | Novo Nordisk Inc | — | Travel and Lodging | In-kind items and services | $685.24 | General |
| 11/19/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $267.43 | General |
| 11/19/2024 | Novo Nordisk Inc | — | Travel and Lodging | In-kind items and services | $235.75 | General |
| 10/15/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $550.00 | General |
| 04/12/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $1,100.00 | General |
| 11/11/2023 | PFIZER LIMITED | XYNTHA (Biological), BENEFIX | Travel and Lodging | In-kind items and services | $10,029.76 | General |
| Category: HEMATOLOGY | ||||||
| 11/11/2023 | PFIZER LIMITED | XYNTHA (Biological), BENEFIX | Travel and Lodging | In-kind items and services | $259.13 | General |
| Category: HEMATOLOGY | ||||||
| 11/11/2023 | PFIZER LIMITED | XYNTHA (Biological), BENEFIX | Travel and Lodging | In-kind items and services | $103.91 | General |
| Category: HEMATOLOGY | ||||||
| 11/11/2023 | PFIZER LIMITED | XYNTHA (Biological), BENEFIX | Travel and Lodging | In-kind items and services | $13.45 | General |
| Category: HEMATOLOGY | ||||||
| 11/09/2023 | Novo Nordisk AS | — | Consulting Fee | Cash or cash equivalent | $2,325.00 | General |
| 10/10/2023 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $3,300.00 | General |
| 06/08/2023 | Novo Nordisk Inc | — | Consulting Fee | Cash or cash equivalent | $11,043.75 | General |
| 06/08/2023 | Novo Nordisk Inc | — | Consulting Fee | Cash or cash equivalent | $1,550.00 | General |
| 06/08/2023 | Novo Nordisk Inc | — | Travel and Lodging | In-kind items and services | $736.60 | General |
| 06/08/2023 | Novo Nordisk Inc | — | Travel and Lodging | In-kind items and services | $427.82 | General |
| 06/08/2023 | Novo Nordisk Inc | — | Travel and Lodging | In-kind items and services | $358.62 | General |
| 06/08/2023 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $229.92 | General |
| 11/17/2022 | Novo Nordisk Inc | — | Consulting Fee | Cash or cash equivalent | $11,062.50 | General |
| 11/17/2022 | Deciphera Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $1,240.00 | Research |
| 11/17/2022 | Novo Nordisk Inc | — | Travel and Lodging | In-kind items and services | $56.00 | General |
| 11/16/2022 | Novo Nordisk Inc | — | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| 07/21/2022 | Mallinckrodt Hospital Products Inc. | — | Consulting Fee | Cash or cash equivalent | $5,720.00 | General |
| 06/22/2022 | Mallinckrodt Hospital Products Inc. | — | Food and Beverage | In-kind items and services | $79.13 | General |
| 06/14/2022 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $550.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING, MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF RIFAXIMIN SOLUBLE DISPERSION SSD TABLETS PLUS LACTULOSE AND RIFAXIMIN EXTENDED INTESTINAL RELEASE EIR TABLETS PLUS LACTULOSE FOR THE TREATMENT OF OVERT HEPATIC ENCEPHALOPATHY OHE. | Bausch Health US, LLC | $1,750 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 3 | 40 | 56 | $5,926 | $3,909 |
| 2021 | 2 | 34 | 73 | $4,304 | $2,786 |
| 2020 | 2 | 63 | 133 | $8,750 | $5,868 |
All Medicare Procedures & Services
7 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 11 | 11 | $2,684 | $1,824 | 68.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 15 | 25 | $2,212 | $1,437 | 65.0% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 14 | 20 | $1,030 | $647.89 | 62.9% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 22 | 53 | $2,544 | $1,655 | 65.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 12 | 20 | $1,760 | $1,132 | 64.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 26 | 60 | $5,280 | $3,449 | 65.3% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2020 | 37 | 73 | $3,470 | $2,419 | 69.7% |
About Dr. Rajender Reddy, M.D
Dr. Rajender Reddy, M.D is a Internal Medicine healthcare provider based in Hammonton, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/19/2007. The National Provider Identifier (NPI) number assigned to this provider is 1467505784.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Rajender Reddy, M.D has received a total of $97,807 in payments from pharmaceutical and medical device companies, with $13,495 received in 2024. These payments were reported across 41 transactions from 8 companies. The most common payment nature is "Consulting Fee" ($78,788).
As a Medicare-enrolled provider, Reddy has provided services to 137 Medicare beneficiaries, totaling 262 services with total Medicare billing of $12,563. Data is available for 3 years (2020–2022), covering 7 distinct procedure/service records.
Practice Information
- Specialty Internal Medicine
- Location Hammonton, NJ
- Active Since 01/19/2007
- Last Updated 01/31/2008
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1467505784
Products in Payments
- XYNTHA (Biological) $10,406
- XIFAXAN (Drug) $1,750
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Hammonton
Rishi Rastogi, Md, MD
Internal Medicine — Payments: $3,344
Dr. Abisoye Fakayode, Md, MD
Internal Medicine — Payments: $1,459
Sonali Bagchi, M.d, M.D
Internal Medicine — Payments: $167.73
Juan Bejaran, Md, MD
Internal Medicine — Payments: $55.55
Dr. Dipesh Patel, Md, MD
Internal Medicine — Payments: $47.75
Dr. Edwin Fernandez, M.d, M.D
Internal Medicine — Payments: $22.76